线粒体ROS抑制可以防止多克索鲁比诱导的乳腺癌细胞迁移和入侵
Tania Capeloa1, Justine A Van de Velde1, Erica Pranzini1,2
1Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
iScience
|July 24, 2025
概括
低致死性多克索鲁比化疗可以通过线粒体活性氧物种 (mtROS) 触发癌细胞迁移. 然而,将 antracyclines 与针对线粒体的抗氧化剂 (如MitoTEMPO) 结合起来,可以防止转移,而不会降低化疗的有效性.
科学领域:
- 在瘤学瘤学.
- 线粒体生物学 线粒体生物学
- 癌症转移研究 癌症转移研究
背景情况:
- 转移是癌症治疗中的一个关键挑战,通常与线粒体的活性氧物种 (mtROS) 生产有关.
- 人环素,像多克索鲁比一样,可以诱导线粒体损伤和随后的mtROS生成.
研究的目的:
- 调查多克索鲁比的次致命剂量是否可以在乳腺癌模型中引发转移.
- 评估针对线粒体的抗氧化剂在预防化疗引起的转移方面的潜力.
主要方法:
- 利用小鼠模型研究小鼠和人类乳腺癌.
- 用于模仿临床场景的多克索鲁比的次致命剂量.
- 评估了mtROS产生,TGFβ通路激活 (Pyk2) 和癌细胞迁移/入侵.
- 测试了MitoTEMPO在预防转移性传播方面的有效性.
主要成果:
- 亚致死的多克索鲁比辛触发了mtROS的产生和激活Pyk2,增强了癌细胞的迁移和入侵.
- doxorubicin 在免疫能力强的小鼠中没有显著地促进转移.
- 米托波完全防止了转移性传播,而不会影响多克索鲁比的抗癌作用.
结论:
- 化疗诱导的mtROS可以促进转移性表型,尽管在这个模型中不完整.
- 针对线粒体的抗氧化剂为缓解化疗引起的转移提供了一个有希望的策略.
- 与抗氧化剂结合人环素可以通过防止癌症传播来改善癌症治疗结果.
相关概念视频
01:46Electron Transport Chain: Complex I and II
15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.0K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K